bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
bluebird bio, Inc. (Nasdaq: BLUE) has announced the completion of its Form 10-Q filing for the quarter ended June 30, 2024, with the Securities and Exchange Commission (SEC). This filing, known as the Q2 2024 Form 10-Q, brings the company up to date with its SEC periodic reporting obligations. The announcement was made from the company's location in Somerville, Massachusetts.
bluebird bio, Inc. (Nasdaq: BLUE) ha annunciato il completamento della sua registrazione del Modulo 10-Q per il trimestre conclusosi il 30 giugno 2024, presso la Securities and Exchange Commission (SEC). Questa registrazione, nota come Modulo 10-Q Q2 2024, aggiorna l'azienda sui suoi obblighi di reporting periodico verso la SEC. L'annuncio è stato fatto dalla sede dell'azienda a Somerville, Massachusetts.
bluebird bio, Inc. (Nasdaq: BLUE) ha anunciado la finalización de su presentación del Formulario 10-Q para el trimestre que finalizó el 30 de junio de 2024, ante la Securities and Exchange Commission (SEC). Esta presentación, conocida como el Formulario 10-Q del segundo trimestre de 2024, actualiza a la empresa respecto a sus obligaciones de reporte periódico ante la SEC. El anuncio se hizo desde la ubicación de la empresa en Somerville, Massachusetts.
bluebird bio, Inc. (Nasdaq: BLUE)는 2024년 6월 30일에 종료된 분기의 10-Q 양식 제출이 완료되었음을 증권 거래 위원회(SEC)에 알렸습니다. 이 제출물은 2024년 2분기 10-Q 양식으로 알려져 있으며, SEC의 정기 보고 의무에 대한 회사의 최신 정보를 제공합니다. 이 발표는 매사추세츠주 서머빌에 있는 회사의 본사에서 이루어졌습니다.
bluebird bio, Inc. (Nasdaq: BLUE) a annoncé la finalisation de son dépôt du formulaire 10-Q pour le trimestre se terminant le 30 juin 2024, auprès de la Securities and Exchange Commission (SEC). Ce dépôt, connu sous le nom de formulaire 10-Q du 2e trimestre 2024, met l'entreprise à jour concernant ses obligations de reporting périodique envers la SEC. L'annonce a été faite depuis le siège de l'entreprise à Somerville, Massachusetts.
bluebird bio, Inc. (Nasdaq: BLUE) hat den Abschluss seiner Einreichung des Formulars 10-Q für das am 30. Juni 2024 endende Quartal bei der Securities and Exchange Commission (SEC) bekannt gegeben. Diese Einreichung, bekannt als 10-Q-Formular für das 2. Quartal 2024, bringt das Unternehmen auf den neuesten Stand seiner regelmäßigen Berichtspflichten gegenüber der SEC. Die Ankündigung erfolgte von dem Standort des Unternehmens in Somerville, Massachusetts.
- Company is now current with SEC reporting obligations
- None.
With the completion of this filing, the Company is now current in its SEC periodic reporting obligations.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240927347484/en/
Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media:
Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
Source: bluebird bio, Inc.
FAQ
What did bluebird bio (BLUE) announce regarding its Q2 2024 Form 10-Q?
Is bluebird bio (BLUE) now current with its SEC reporting obligations?
When did the reporting period for bluebird bio's (BLUE) latest Form 10-Q end?
Where is bluebird bio (BLUE) headquartered?
